Among the companies with shares expected to actively trade in Monday's session are Mattel Inc. (MAT), Endocyte Inc. (ECYT) and Citigroup Inc. (C)

Mattel's first-quarter profit fell 53% on expenses tied to the toy maker's purchase of HIT Entertainment and as an increase in demand overseas couldn't offset a decline in the mature North American market. Shares slid 6.2% to $32.03 in recent premarket trading as the top line results missed Wall Street's expectations for the second consecutive quarter. Shares of rival toy maker Hasbro Inc. (HAS), which is due to report results next week, dropped 5.3% to $34.25.

Merck & Co. (MRK) has agreed to pay $120 million upfront to Endocyte, with additional payouts of up to $880 million, to develop and market the experimental cancer drug vintafolide as the drug maker looks to bring more drugs to market. Endocyte's shares more than doubled premarket, rising 111% to $8.

Citigroup's first-profit remained virtually flat from a year earlier at $2.9 billion, through revenue particularly from equity and debt capital markets operations improved from the fourth-quarter. Shares of Citigroup rose 2.1% to $34.10 premarket.

Baxter International Inc. (BAX) and Halozyme Therapeutics Inc. (HALO) received a Food and Drug Administration request for additional information related to the long-term use of their investigational product called HyQ. Shares of Halozyme tumbled 20% to $9 premarket, while Baxter's shares traded down 2.6% to $56.51.

Mark Cuban has taken a 7.4% stake in video ringtone maker Vringo Inc. (VRNG), a disclosure that comes a day after the billionaire made an investment in another applications maker. Shares jumped 22% to $3.71 premarket

The California state appeals court overturned a ruling against Boeing Co. (BA) that had awarded $603 million to ICO Global Communications Ltd., now known as Pendrell Corp. (PCO), in a 2008 lawsuit over allegations Boeing breached a contract to build a world-wide satellite-communications network. Pendrell shares fell 38% to $1.35 premarket.

Bank of America/Merrill Lynch upgraded its stock-investment rating on Caterpillar Inc. (CAT) to buy from neutral, saying recent pullback in stock price "presents an attractive entry point into a stock with a strong growth profile and high [free cash flow] yield at a discounted valuation." The firm said Caterpillar's low multiple "reflects a lot of macro-economic uncertainty," but the firm sees ongoing strength in North America, "stabilizing Europe & Asia, and better-than-expected progress in execution turnaround." Caterpillar's shares traded up 1.7% to $107.65 in recent premarket trading.

Dreams Inc. (DRJ) said it has signed a definitive merger agreement with Fanatics Inc., an online seller of licensed sports products. Under the agreement Fanatics will acquire all the outstanding shares of Dreams, a technology-driven multi-channel retailer, for $3.45 per share in cash. The offer represents a 32% premium over Dreams' Friday closing price. Shares of Dreams jumped 45% to $3.79 premarket.

 
   Watchlist 
 

Alliance Data Systems Corp. (ADS) said it saw reduced charge-offs and a lower delinquency rate for the private-label cards it oversees in March.

Booz Allen & Hamilton Inc.'s (BAH) San Antonio office was removed from the U.S. government's excluded parties list system and is now eligible to compete for new federal contracts.

Hallwood Group Inc. (HWG) said its independent public accounting firm included a going concern opinion in its Form 10-K filing for 2011, citing uncertainty related to ongoing litigation.

Standard & Poor's Ratings Services lowered its credit rating on Kratos Defense & Security Solutions Inc. (KTOS) one notch further into junk territory, citing the defense supplier's lower-than-expected 2011 earnings.

Standard and Poor's Ratings Services boosted its ratings on PNM Resources Inc. (PNM) to investment grade, pointing to the utility operator's focus on its core electric operations.

Procter & Gamble Co. (PG) said Friday it will raise its quarterly dividend 7%, as the world's largest consumer-goods company looks to boost shareholder return.

-Edited by Corrie Driebusch and Nathalie Tadena; write to corrie.driebusch@dowjones.com

Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Halozyme Therapeutics Charts.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Halozyme Therapeutics Charts.